Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
MRI
Secondary progressive MS
disability
health-related quality of life
outcome measures
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
31
12
2021
medline:
14
6
2022
entrez:
30
12
2021
Statut:
ppublish
Résumé
Health-related quality of life (HRQOL) outcomes are often included as secondary outcomes in clinical trials in secondary progressive MS (SPMS), but little is known about the longitudinal association of HRQOL and clinical and imaging outcome measures in SPMS. To assess the association of change in clinical and imaging outcomes with HRQOL in people with SPMS. We used data from ASCEND, a large randomized controlled trial ( HRQOL measures were most associated with EDSS and T25FW, less so with NHPT and SDMT, and not associated with lesional and volumetric imaging outcomes. Worsening of the EDSS and T25FW was associated with two commonly used HRQOL measures. These outcomes therefore appear to be more patient relevant than either the NHPT or SDMT in the context of a 2-year clinical trial.
Sections du résumé
BACKGROUND
Health-related quality of life (HRQOL) outcomes are often included as secondary outcomes in clinical trials in secondary progressive MS (SPMS), but little is known about the longitudinal association of HRQOL and clinical and imaging outcome measures in SPMS.
OBJECTIVE
To assess the association of change in clinical and imaging outcomes with HRQOL in people with SPMS.
METHODS
We used data from ASCEND, a large randomized controlled trial (
RESULTS
HRQOL measures were most associated with EDSS and T25FW, less so with NHPT and SDMT, and not associated with lesional and volumetric imaging outcomes.
DISCUSSION
Worsening of the EDSS and T25FW was associated with two commonly used HRQOL measures. These outcomes therefore appear to be more patient relevant than either the NHPT or SDMT in the context of a 2-year clinical trial.
Identifiants
pubmed: 34965774
doi: 10.1177/13524585211063623
pmc: PMC9189721
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1286-1298Références
JAMA Neurol. 2014 Nov;71(11):1386-93
pubmed: 25178496
Clin Neuropsychol. 2010 Oct;24(7):1131-45
pubmed: 20830649
Arch Neurol. 1992 Dec;49(12):1237-42
pubmed: 1449401
Neurology. 2019 Nov 19;93(21):e1921-e1931
pubmed: 31641014
Brain. 2001 May;124(Pt 5):962-73
pubmed: 11335698
Lancet Neurol. 2005 Sep;4(9):556-66
pubmed: 16109362
Mult Scler. 2019 Nov;25(13):1781-1790
pubmed: 30334474
Acta Neurol Scand. 2001 Nov;104(5):257-61
pubmed: 11696017
Neurology. 2005 Apr 12;64(7):1144-51
pubmed: 15824338
Lancet Neurol. 2018 May;17(5):405-415
pubmed: 29545067
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Neurology. 2021 Jan 5;96(1):e111-e120
pubmed: 33106389
Mult Scler. 2020 Oct;26(12):1540-1549
pubmed: 31517591
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
J Neurol Sci. 2005 Apr 15;231(1-2):29-34
pubmed: 15792817
Mult Scler. 2022 Feb;28(2):289-299
pubmed: 34100297
Mult Scler. 2015 Feb;21(2):171-9
pubmed: 25013153
Mult Scler. 2017 Apr;23(5):704-710
pubmed: 28206828
J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):841-4
pubmed: 17332049
J Neurol. 2012 Feb;259(2):237-45
pubmed: 21863390
Mult Scler. 2017 Apr;23(5):711-720
pubmed: 28206826
Neuroimage. 2002 Sep;17(1):479-89
pubmed: 12482100
Arch Neurol. 2004 May;61(5):679-86
pubmed: 15148144
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Brain Behav. 2018 Jan 05;8(2):e00875
pubmed: 29484253
Eur J Neurol. 2002 Sep;9(5):497-502
pubmed: 12220381